Fennec Pharmaceuticals Inc. (TSE:FRX - Get Free Report) shares passed above its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of C$10.93 and traded as high as C$11.67. Fennec Pharmaceuticals shares last traded at C$11.67, with a volume of 100 shares trading hands.
Fennec Pharmaceuticals Stock Down 2.8%
The company has a market cap of C$224.47 million, a PE ratio of -197.18 and a beta of 0.25. The company's 50 day moving average is C$11.11 and its 200 day moving average is C$9.54. The company has a current ratio of 7.80, a quick ratio of 10.17 and a debt-to-equity ratio of -620.83.
Insiders Place Their Bets
In other Fennec Pharmaceuticals news, Director Rostislav Christov Raykov sold 16,667 shares of Fennec Pharmaceuticals stock in a transaction that occurred on Friday, May 16th. The shares were sold at an average price of C$9.49, for a total transaction of C$158,203.16. Also, Director Jeffrey Hackman acquired 15,000 shares of the firm's stock in a transaction on Monday, May 19th. The shares were acquired at an average price of C$9.77 per share, with a total value of C$146,580.00. Insiders have sold a total of 39,913 shares of company stock worth $402,086 in the last three months. Corporate insiders own 16.20% of the company's stock.
About Fennec Pharmaceuticals
(
Get Free Report)
Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is primarily engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its lead product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children.
Further Reading
Before you consider Fennec Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fennec Pharmaceuticals wasn't on the list.
While Fennec Pharmaceuticals currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
